Replies to post #107645 on Anavex Life Sciences Corp (AVXL)

[nidan7500]

"If adaptive trials and precision medicine become vogue, how will FDA procedures and by proxy, biotech investing change? "

I am not an expert but will say what I think. The massive overhead, costs and results of the past 20 years would normally have stopped the FDA processes in their tracks if it were a private business. The trial and error process has proven itself to have severe limitations in this application. Precision medicine can change that.

I would like to think that precision medicine would answer the questions of (for example): How is Hemostasis measured? If the answer to that question existed today and if Dr. M's thesis of it's correlation to CNS diseases proves true, then precision medicine would/could be used to target certain cell development. To me it suggests a practice of medicine with confidence approaching certainty of a predicted outcome.

Dr. Peter Senge "The fifth discipline " describe 3 levels of knowledge (what we know, what we don't know but we know we don't know it and what we do not know we do not know) Learning occurs at the interface of the first and second stage. Example, if we knew today how to measure cell homeostasis could we treat AD patients?